Browse investments

Invest in BioAtla Inc on Stash

BioAtla, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL. It is developing BA3021, which is a CAB ADC targeting ROR2. Its BA3071 is a CAB anti-CTLA-4 antibody. It also leverages CAB technology to develop bispecific antibodies, which bind both a tumor-specific antigen and a T cell receptor using CAB antigen-binding domains.

To buy fractional shares of BioAtla Inc stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Ticker: BCAB

BioAtla Inc

$0.78

-6.02%

(1W)

$

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years. Historical performance data are provided “as is” and solely for information purposes, is not advice or for trading purposes, does not reflect an investment strategy, may be subject to pricing delays, should not be used for tax reporting, may not reflect actual performance, and are gross of Stash fees. Market data provided by Thomson Reuters (Refinitiv). ©2024 Thomson Reuters. Stash cannot and does not represent or guarantee that any of the information available via Refinitiv is accurate, reliable, current, complete or appropriate for your needs. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine performance and yield are not a reliable indicator of current and future results.

BCAB Performance Breakdown

Share Price

$0.78

Today's change

1.23%

Year to date change (YTD)

27.87%

Dividend yield

0.0

Last dividend paid

N/A

Last dividend pay date

N/A

About BCAB

BioAtla, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL. It is developing BA3021, which is a CAB ADC targeting ROR2. Its BA3071 is a CAB anti-CTLA-4 antibody. It also leverages CAB technology to develop bispecific antibodies, which bind both a tumor-specific antigen and a T cell receptor using CAB antigen-binding domains.

BioAtla Inc Stock Ticker

BCAB

For more information

https://www.bioatla.com/

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years. Historical performance data are provided “as is” and solely for information purposes, is not advice or for trading purposes, does not reflect an investment strategy, may be subject to pricing delays, should not be used for tax reporting, may not reflect actual performance, and are gross of Stash fees. Market data provided by Thomson Reuters (Refinitiv). ©2024 Thomson Reuters. Stash cannot and does not represent or guarantee that any of the information available via Refinitiv is accurate, reliable, current, complete or appropriate for your needs. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine performance and yield are not a reliable indicator of current and future results.

Invest in BioAtla Inc on Stash

BioAtla, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL. It is developing BA3021, which is a CAB ADC targeting ROR2. Its BA3071 is a CAB anti-CTLA-4 antibody. It also leverages CAB technology to develop bispecific antibodies, which bind both a tumor-specific antigen and a T cell receptor using CAB antigen-binding domains.

To buy fractional shares of BioAtla Inc stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Certain companies are volatile

Certain companies can be volatile, meaning the stock price fluctuates significantly. Don’t put all your eggs into one basket and remember to keep the Stash Way in mind when you invest.

BioAtla Inc stock news

CNBC

Amazon's Ring launches AI-generated security alerts

Amazon-owned Ring is rolling out AI-generated summaries of footage captured by its doorbells and cameras. The tool uses artificial intelligence to generate text summaries of motion activity captured by Ring doorbells and cameras, which are then displayed as a phone notification.

6 months ago

24/7 Wall Street

Meta Platforms (NASDAQ: META) Price Prediction and Forecast 2025-2030 for June 25

Shares of Meta Platforms Inc. (NASDAQ: META) gained 2.01% over the past five trading sessions, bringing the stock's year-to-date gain to 18.85%.

6 months ago

Business Insider

Boeing didn't train factory staff well enough in the lead up to the Alaska Airlines 737 Max blowout, NTSB says

The NTSB released a summary of their investigation into the Alaska Airlines door plug blowout in 2024. It cited Boeing's failure to "provide adequate training, guidance, and oversight" to its workers.

6 months ago

See It Market

Will Strong Dividend-Increase Trends Continue Amid Macro Uncertainty?

As we put the finishing touches on a first half that was littered with uncertainty, a small treasure is seen in global dividend trends. Thirty percent of the companies Wall Street Horizon tracks announced shareholder-payout increases in the second quarter—the best Q2 mark going back to 2021.

6 months ago

Why invest with Stash?

Fractional shares

Thousands of stocks and ETFs. No investing minimums.

Unlimited trades

Plus no add-on trading commission fees.^†

Diversification analysis

Custom investment recommendations can help you diversify.

Automatic investing

Dividend reinvestment,⁸ recurring investments, and more.

The Stock-Back® Card

We’ll give you matching stock in companies you shop at.¹

Learn how to invest

Get professional advice and education at every step.

How to buy BioAtla Inc stock on Stash

Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.

BioAtla Inc’s share price is determined by its bid-ask spread, which is the difference between the price that buyers are willing to pay and the price that sellers are willing to accept. BioAtla Inc’s price can fluctuate throughout the course of each trading day—when you buy BioAtla Inc through Stash, we execute the market order during our next available trading window (we have two a day). At Stash, we don’t recommend trying to predict the market when buying investments. We believe it can be a better strategy to buy quality investments you believe in, then hang onto them.

Use our historic performance chart to see real-time BioAtla Inc stock price and the BioAtla Inc news feed to help further your research before investing in fractional shares with any dollar amount you choose.

Stash offers two subscription plans: Stash Growth and Stash+.

Each plan can help you reach different goals and offers a unique combination of financial accounts and features. All plans include access to a personal brokerage account—also known as your personal investment account. You can use your Stash personal portfolio to purchase any of the available investments on our platform, as well as access our suite of automatic saving and investing tools. Learn more about Stash pricing.

Once your market order of BioAtla Inc stock is complete, you'll officially be a shareholder of BioAtla Inc!